ReviewJournal of pain research2025
Gabapentinoids-Induced Rhabdomyolysis/Myopathy: Clinical Characteristics, Management, Outcomes, and Critical Safety Alerts.
Review in Journal of pain research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Post-marketing safety evaluation of mirogabalin using the JADER database.Frontiers in pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Gabapentinoids, increasingly prescribed for neuropathic pain, demonstrate undercharacterized muscular toxicity risks despite perceived safety advantages over opioids, this includes the potential to induce rhabdomyolysis-a critical condition characterized by rapid release of intracellular contents into the systemic circulation due to muscle cell injury, ultimately leading to systemic complications. Methods: A systematic global review (inception-2024) identified 19 gabapentinoid-induced rhabdomyolysis cases across 15 databases, analyzed via standardized protocols for clinical patterns, management, and outcomes. Results: Cases (median age 63; 52.6% male) manifested rapid symptom onset (≤7 days in 52.9%), severe creatine phosphokinase(CPK) elevation (median 3,095 U/L), and renal impairment (78.9%). All patients discontinued gabapentinoids, with 57.9% receiving hydration/alkalinization and 31.6% requiring dialysis. Biochemical resolution occurred in 78.9% (median 14 days), though one mortality resulted from comorbid complications. Naranjo assessments confirmed probable causality in 84.2% of cases. Of note, a significant majority of patients (89.5%) presented with multiple comorbidities (such as hypertension, diabetes, and hyperlipidemia) and received polypharmacy. Particularly when co-administered with statins (as observed in 7 cases where symptom onset occurred following combination therapy), drug-drug interactions may lead to accumulation of medicinal products, thereby significantly increasing the risk of rhabdomyolysis. Conclusion: This study provides the first evidence-based framework for gabapentinoid myotoxicity monitoring, emphasizing renal function-guided dosing, early CPK surveillance, and drug interaction vigilance. Clinicians should consider gabapentinoid cessation in unexplained myalgia with CK >3×ULN, particularly in high-risk populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.